CN113861191B - 抑制cdk4/6活性化合物的晶型及其应用 - Google Patents
抑制cdk4/6活性化合物的晶型及其应用 Download PDFInfo
- Publication number
- CN113861191B CN113861191B CN202111208432.8A CN202111208432A CN113861191B CN 113861191 B CN113861191 B CN 113861191B CN 202111208432 A CN202111208432 A CN 202111208432A CN 113861191 B CN113861191 B CN 113861191B
- Authority
- CN
- China
- Prior art keywords
- compound
- crystal form
- xrd
- crystal
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111208432.8A CN113861191B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/092194 | 2018-06-21 | ||
CN2018092194 | 2018-06-21 | ||
CN202111208432.8A CN113861191B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
CN201980037275.3A CN112424202B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
PCT/CN2019/092239 WO2019242719A1 (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980037275.3A Division CN112424202B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113861191A CN113861191A (zh) | 2021-12-31 |
CN113861191B true CN113861191B (zh) | 2023-09-19 |
Family
ID=68983152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980037275.3A Active CN112424202B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
CN202111208432.8A Active CN113861191B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980037275.3A Active CN112424202B (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US12043622B2 (es) |
EP (1) | EP3812386A4 (es) |
JP (1) | JP7430656B2 (es) |
KR (1) | KR20210024004A (es) |
CN (2) | CN112424202B (es) |
AU (1) | AU2019290722B2 (es) |
BR (1) | BR112020026052A2 (es) |
CA (1) | CA3104365A1 (es) |
EA (1) | EA202190036A1 (es) |
IL (1) | IL279579B2 (es) |
MX (1) | MX2020013847A (es) |
PH (1) | PH12020552236A1 (es) |
SG (1) | SG11202012858QA (es) |
TW (1) | TWI786303B (es) |
WO (1) | WO2019242719A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117222411A (zh) * | 2021-03-24 | 2023-12-12 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
CN115872923B (zh) * | 2022-12-29 | 2023-04-28 | 成都泰和伟业生物科技有限公司 | 一种化合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
WO2017102796A1 (en) * | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
WO2017206924A1 (zh) * | 2016-06-01 | 2017-12-07 | 贝达药业股份有限公司 | 抑制蛋白激酶活性化合物的晶型及其应用 |
CN107690431A (zh) * | 2015-07-08 | 2018-02-13 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺内酰胺衍生物 |
CN107849012A (zh) * | 2015-04-28 | 2018-03-27 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105294655B (zh) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
CN104592251B (zh) * | 2015-01-23 | 2019-10-01 | 上海复星医药产业发展有限公司 | 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途 |
DK3559000T3 (da) * | 2016-12-22 | 2022-06-07 | Betta Pharmaceuticals Co Ltd | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf |
WO2019035008A1 (en) * | 2017-08-15 | 2019-02-21 | Beijing Xuanyi Pharmasciences Co., Ltd. | INHIBITORS OF CDK4 / 6 AND THEIR USE |
-
2019
- 2019-06-21 WO PCT/CN2019/092239 patent/WO2019242719A1/zh unknown
- 2019-06-21 TW TW108121799A patent/TWI786303B/zh active
- 2019-06-21 SG SG11202012858QA patent/SG11202012858QA/en unknown
- 2019-06-21 AU AU2019290722A patent/AU2019290722B2/en active Active
- 2019-06-21 KR KR1020217001384A patent/KR20210024004A/ko not_active Application Discontinuation
- 2019-06-21 MX MX2020013847A patent/MX2020013847A/es unknown
- 2019-06-21 CN CN201980037275.3A patent/CN112424202B/zh active Active
- 2019-06-21 US US17/254,097 patent/US12043622B2/en active Active
- 2019-06-21 BR BR112020026052-5A patent/BR112020026052A2/pt unknown
- 2019-06-21 CA CA3104365A patent/CA3104365A1/en active Pending
- 2019-06-21 EP EP19822566.6A patent/EP3812386A4/en active Pending
- 2019-06-21 JP JP2020571503A patent/JP7430656B2/ja active Active
- 2019-06-21 CN CN202111208432.8A patent/CN113861191B/zh active Active
- 2019-06-21 IL IL279579A patent/IL279579B2/en unknown
- 2019-06-21 EA EA202190036A patent/EA202190036A1/ru unknown
-
2020
- 2020-12-21 PH PH12020552236A patent/PH12020552236A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849012A (zh) * | 2015-04-28 | 2018-03-27 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
CN107690431A (zh) * | 2015-07-08 | 2018-02-13 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺内酰胺衍生物 |
CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
WO2017102796A1 (en) * | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
WO2017206924A1 (zh) * | 2016-06-01 | 2017-12-07 | 贝达药业股份有限公司 | 抑制蛋白激酶活性化合物的晶型及其应用 |
Non-Patent Citations (7)
Title |
---|
A general and enantiodivergent method for the asymmetric synthesis of piperidine alkaloids: concise synthesis of (R)-pipecoline, (S)-coniine and other 2-alkylpiperidines;Juan Etxebarria等;《Tetrahedron》;20070825;第63卷;第11423页 * |
Claus U. Jessen等.Synthesis of N-protected 14C-Labelled (2E)-5-amino-5-methylhex-2-enoic acid analogues.《Journal of Labelled Compounds and Radiopharmaceuticals》.2001,第44卷(第4期),第266页. * |
Convenient in situ synthesis of nonracemic N-protected β-amino aldehydes from β-amino acids. Applications in Wittig reactions and heterocycle synthesis;Simon B.Davied等;《Tetrahedron Letters》;19990205;第40卷;第1230-1231页 * |
r-Methyl Polyamines: Efficient Synthesis and Tolerance Studies in Vivo and in Vitro. First Evidence for Dormant Stereospecificity of Polyamine Oxidase;Aki J. Ja¨rvinen等;《J. Med. Chem.》;20061231;第49卷;第400页 * |
Simon B.Davied等.Convenient in situ synthesis of nonracemic N-protected β-amino aldehydes from β-amino acids. Applications in Wittig reactions and heterocycle synthesis.《Tetrahedron Letters》.1999,第40卷第1230-1231页. * |
Synthesis of N-protected 14C-Labelled (2E)-5-amino-5-methylhex-2-enoic acid analogues;Claus U. Jessen等;《Journal of Labelled Compounds and Radiopharmaceuticals》;20010417;第44卷(第4期);第266页 * |
Synthesis of Peptidyl Ene Diones: Selective Inactivators of the Cysteine Proteinases;Paul Darkins等;《Chem Biol Drug Des》;20071231;第69卷;第170-179页 * |
Also Published As
Publication number | Publication date |
---|---|
MX2020013847A (es) | 2021-04-28 |
CA3104365A1 (en) | 2019-12-26 |
JP7430656B2 (ja) | 2024-02-13 |
JP2021529175A (ja) | 2021-10-28 |
EA202190036A1 (ru) | 2021-03-24 |
AU2019290722A1 (en) | 2021-01-28 |
US20210261546A1 (en) | 2021-08-26 |
PH12020552236A1 (en) | 2021-06-28 |
EP3812386A4 (en) | 2022-03-30 |
TW202016114A (zh) | 2020-05-01 |
IL279579B (en) | 2022-10-01 |
AU2019290722B2 (en) | 2023-12-21 |
CN112424202A (zh) | 2021-02-26 |
CN112424202B (zh) | 2021-09-17 |
WO2019242719A1 (zh) | 2019-12-26 |
SG11202012858QA (en) | 2021-02-25 |
IL279579A (en) | 2021-03-01 |
TWI786303B (zh) | 2022-12-11 |
EP3812386A1 (en) | 2021-04-28 |
BR112020026052A2 (pt) | 2021-03-23 |
CN113861191A (zh) | 2021-12-31 |
US12043622B2 (en) | 2024-07-23 |
IL279579B2 (en) | 2023-02-01 |
KR20210024004A (ko) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7383652B2 (ja) | B-rafキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
CN113861191B (zh) | 抑制cdk4/6活性化合物的晶型及其应用 | |
CN109689641B (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
TWI675839B (zh) | 一種jak激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法 | |
US20180009804A1 (en) | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor | |
WO2016169422A1 (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
WO2023093861A1 (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
JP2023540491A (ja) | 突然変異型egfr阻害化合物およびその適用 | |
CN110551142A (zh) | 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用 | |
CN111100117B (zh) | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 | |
WO2023093859A1 (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
WO2023083356A1 (zh) | 固体形式的氮杂稠环酰胺类化合物及其用途 | |
CN116768856A (zh) | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 | |
CN104119321B (zh) | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 | |
EA043251B1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
CN112654623B (zh) | 新型氮杂三环类化合物的盐型、晶型及其用途 | |
WO2021249450A1 (zh) | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 | |
CN114392258B (zh) | 一种4H-吡喃并[2,3-c]吡啶-4-酮类化合物药物制剂及其制备方法 | |
CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 | |
KR20220159457A (ko) | Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도 | |
CN117486813A (zh) | N-二取代苯基丙烯酰胺类化合物及其药物组合物和用途 | |
CN118772111A (zh) | 一种取代的氨基嘧啶类化合物、药物组合物及其用途 | |
CN117794913A (zh) | 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |